Endocrine research
Ipamorelin vs CJC-1295
Selective GHRP research beside extended GHRH analogue literature.
Overview
This comparison separates Ipamorelin and CJC-1295 for laboratory reference—not product selection.
Ipamorelin: Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile and ability to produc…
CJC-1295: Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 with DAC, this versio…
Differences
- Both appear in Tissue repair & recovery literature, but mechanistic framing differs.
- The useful distinction is research question and receptor context—not relative potency or practical ranking.
Mechanism
Ipamorelin: Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile a…
CJC-1295: Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 w…
Pharmacology
Ipamorelin: Pharmacokinetic detail should be read from primary literature.
CJC-1295: Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 w…
Research
Ipamorelin: GLP-1 & metabolic: Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety…
CJC-1295: Tissue repair & recovery: Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. U…
Summary
Distinction
- AXIOM does not provide dosing, administration, or protocol guidance.
- Catalogue links appear only where AXIOM lists a research-use product.
- Reference-only compounds remain comparison terms without implying availability.
References
- pubmed.ncbi.nlm.nih.gov/9849822/
- pubmed.ncbi.nlm.nih.gov/25331030/
- pubmed.ncbi.nlm.nih.gov/10496658/
- pubmed.ncbi.nlm.nih.gov/10373343/
- pubmed.ncbi.nlm.nih.gov/11735244/
- pubmed.ncbi.nlm.nih.gov/16352683/
- pubmed.ncbi.nlm.nih.gov/17018654/
- pubmed.ncbi.nlm.nih.gov/15817669/
Questions
Does this page recommend Ipamorelin or CJC-1295?
No. It is an editorial comparison for research context only.
Does AXIOM provide protocol guidance?
No. Protocol and dosing decisions belong with qualified laboratory teams and source literature.
Available from AXIOM
Catalogue
Labelled strengths and batch records where available.